Boston Scientific rises 4.8% as valuation still points below fair value

Key Facts

As investors remain selective toward healthcare names with mixed valuation signals, Boston Scientific shares rose 4.8% in a GuruFocus note. The report said the stock still trades below fair value according to GF Value™. It also said the GF Score™ was 74/100 and insider buying totaled $0.6 million.

That leaves the market treating the move as a valuation story rather than a fresh operating catalyst, while supportive fundamentals still sit in the background. GuruFocus placed GF Value™ at $45.14 versus an estimated fair value of $105.54. In that framework, profitability and growth signals, along with insider buying, are supportive but do not on their own reset the valuation picture.

At the 2026-07-01 close, BSX ended at $43.06, with a daily range of $42.71 to $43.76, according to market data. The current level sits close to the lower end of that recent range, so follow-through will likely depend on how investors continue to weigh valuation versus sector sentiment. The near-term calendar does not show an immediate company-specific catalyst, keeping attention on price momentum and broader healthcare flows.